Cefetamet Pivoxil in the Treatment of Pharyngitis/Tonsillitis in Children and Adults

Drugs - Tập 47 - Trang 27-34 - 2012
J. P. Guggenbichler1
1Department of Paediatrics, Universitätsspital, Erlangen, Germany

Tóm tắt

Between 15 and 35% of pharyngeal infections are attributable to Group A β-haemolytic streptococci. Streptococcal pharyngitis is one of the most common infections in adolescents and children. A specific diagnosis of pharyngitis can be obtained only by isolating organisms in culture. The current treatment of choice for streptococcal pharyngitis/tonsillitis is a 10-day course of phenoxymethylpenicillin (penicillin V); however, unresolved problems concerning the use of penicillin include the timing of therapy, appropriate therapy for treatment failures, chronic carriers and those with frequent recurrences. In addition, failure rates of 10 to 35% have been reported with oral phenoxymethylpenicillin. Effective treatment alternatives in this indication include oral cephalosporin agents or penicillin/β-lactamase inhibitor combinations. The oral cephalosporins offer the advantage of an improved pharmacokinetic profile, once- or twice-daily administration, a shorter (7-day) regimen, and a low incidence of adverse effects, although these advantages must be balanced against the broad spectrum of these agents (broader than is necessary) and their cost. Clinical trials conducted with cefetamet pivoxil, a new oral third generation cephalosporin, in both adults and children with pharyngitis/tonsillitis indicate that this agent offers an effective alternative for phenoxymethylpenicillin in this indication.

Tài liệu tham khảo

Bass JW. Antibiotic management of streptococcal group A pharyngitis. Pediatric Infectious Disease Journal 10: S43–S49, 1991 Bisno AL. Group A streptococcal infections and acute rheumatic fever. New England Journal of Medicine 325: 783–793, 1991 Block SL, Hedrick JA, Tyler RT. Comparative study of the effectiveness of cefixime and penicillin V for the treatment of streptococcal pharyngitis in children and adolescents. Pediatric Infectious Disease Journal 11: 919–925, 1992 Brook L. The role of β lactamase producing bacteria in the persistence of streptococcal tonsillar infections. Reviews of Infectious Diseases 6: 601–607, 1984 Cherry J. Pharyngitis, (pharyngitis, tonsillitis, tonsillopharyngitis, and nasopharyngitis) In J.D. Cherry (Ed.) Textbook of pediatrie infectious diseases, 3rd ed., pp. 159–166, Saunders Co., Philadelphia, 1992 Corbach SL, Bartlett JG. Anaerobic infections (three parts). New England Journal of Medicine 290: 177–184, 1237–1245, 1289–1294, 1974 Gerber MA. Comparison of throat cultures and rapid strep test for diagnosis of streptococcal pharyngitis. Pediatrie Infectious Disease Journal 8: 820–824, 1989 Gerber MA, Randolph MF, DeMeo KK, Kaplan EL. Lack of impact of early antibiotic therapy for streptococcal pharyngitis on the recurrence rate. Journal of Pediatrics 117: 853–868, 1990 Guggenbichler JP. Relative klinische bioverfügbarkeit von antibiotika bei kindern. Padiatrie und Padologie 17: 565–584, 1982 Guggenbichler JP, Überall M. Behandlung der streptokokkenton-sillitis. Antibiotika Monitor 34: 121–132, 1992 Harrison HR, Magder LS, Boyce WT. Acute Chlamydia trachomatis respiratory tract infection in childhood. Serologie evidence. American Journal of Diseases of Children 140: 1068–1071, 1986 Kaplan EL. Delayed treatment for strep throat. Pediatrie Infectious Disease Journal 6: 1140, 1987 Melish ME, Hicks RM, Larson EJ. Mucocutaneous lymphnode syndrome in the USA. American Journal of Diseases of Children 130: 599–607, 1976 Mufson MA. Mycoplasma hominis 1 in respiratory tract infections. Annals of the New York Academy of Sciences 174: 798–808, 1970 Oberall M, Guggenbichler JP. Compliance als effektivitätsfaktor bei der penicillinbenandlung von Streptokokken a infektionen. Pädiatrische Praxisin press, 1994b Peixoto E, Ramet J, Kissling M. Cefetamet pivoxil in pharyngotonsillitis due to group A beta-hemolytic streptococci. Curent Therapeutic Research 53: 694–706, 1993 Peter G. Streptococcal pharyngitis: Current therapy and criteria for evaluation of new agents. Reviews of Infectious Diseases 14 (Suppl. 2): S218–S223, 1992 Pichichero ME. The rising incidence of penicillin treatment failures in group A streptococcal tonsillopharyngitis: an emerging role for the cephalosporines. Pediatrie Infectious Disease Journal 10: S50–S55, 1991 Raich T, Allerberger FJ, Sandholzer Ch, Guggenbichler JP. Akute Tonsillitis: klinische Symptomatik, bakteriologische Kultur und Schnelltest als Entscheidungskriterium für den Antibiotikaeinsatz. Wiener Klinische Wochenschrift 102: 111–114, 1990 Ramet J, Pierard D, Vandenberghe P, DeBoeck K. Comparative study of cefetamet pivoxil and penicillin V in the treatment of group A beta hemolytic streptococcal pharyngitis. Chemotherapy 38 (Suppl. 2): 33–37, 1992 Stillerman M. Comparison of oral cephalosporines with penicillin therapy for group A streptococcal pharyngitis. Pediatrie Infectious Disease Journal 5: 649–654, 1986 Tanz RR, Shulman ST, Sroka PA, Marubio S, Brook I, et al. Lack of influence of β streptococci after treatment of acute pharyngitis. Journal of Pediatrics 117: 859–863, 1990 Tilz B, Guggenbichler JP. Influence of various new oral cephalosporins on composition and resistance behaviour of fecal flora. Abstract no. 6005, 18th ICC, Stockholm, 1993 Überall M, Guggenbinbichler JP. Compliance als Effektivitätsfaktor bei der Penicillinbehandlung von Streptokokken A Infecktionen. Pädiatrische Praxis: in press, 1994a Überall M, Guggenbichler JP. Copathogemität β lactamase bildender S. aureus, H. influenzae und Bacteroides fragilis ein Mythos? Monatsschrift für Kinderheilkunde: in press, 1994a Walker SH. The respiratory manifestations of acute H. influenzae infections. Journal of Pediatrics 62: 386–392, 1963